177 results on '"Soma, Lorinda A."'
Search Results
2. Cytotoxic peripheral T-cell lymphomas and EBV-positive T/NK-cell lymphoproliferative diseases: emerging concepts, recent advances, and the putative role of clonal hematopoiesis. A report of the 2022 EA4HP/SH lymphoma workshop
3. Follicular helper T-cell lymphomas: disease spectrum, relationship with clonal hematopoiesis, and mimics. A report of the 2022 EA4HP/SH lymphoma workshop
4. Emerging entities: high-grade/large B-cell lymphoma with 11q aberration, large B-cell lymphoma with IRF4 rearrangement, and new molecular subgroups in large B-cell lymphomas. A report of the 2022 EA4HP/SH lymphoma workshop
5. Correction to: The many faces of nodal and splenic marginal zone lymphomas. A report of the 2022 EA4HP/SH lymphoma workshop
6. Genomic landscape of Epstein–Barr virus-positive extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue
7. Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell Lymphoma
8. Entrustable Professional Activities in Hematopathology Pathology Fellowship Training: Consensus Design and Proposal
9. Anaplastic Large Cell Lymphoma: Contemporary Concepts and Optimal Management
10. Significance of CD10-positive clonal B cell populations identified by flow cytometry in histologically benign gastric biopsies
11. Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution Experience
12. Acquired CD38 Gene Deletion as a Mechanism of Tumor Antigen Escape in Multiple Myeloma
13. Fibrin-associated large B-cell lymphoma shows frequent mutations related to immune surveillance and PTEN
14. Hyper‐CVAD versus dose‐adjusted EPOCH as initial treatment for adults with acute lymphoblastic leukemia
15. Anaplastic Large Cell Lymphoma: Contemporary Concepts and Optimal Management
16. Donor derived T-cell large granular lymphocyte leukemia after cord blood transplant for pediatric T-cell lymphoblastic leukemia
17. Ibrutinib response in a patient with refractory mixed essential cryoglobulinemia
18. Phase II study of dose-adjusted EPOCH as initial therapy for adults with high-risk acute lymphoblastic leukemia
19. Acquired CD38gene deletion as a mechanism of tumor antigen escape in multiple myeloma
20. Evaluating breast lymphoplasmacytic infiltrates: a multiparameter immunohistochemical study, including assessment of IgG4
21. Dose-Adjusted EPOCH Versus Hypercvad As Initial Treatment for Adults with Acute Lymphoblastic Leukemia (ALL): A Retrospective Matched Cohort Comparison
22. CD19 CAR-T cells of defined [CD4.sup.+]:[CD8.sup.+] composition in adult B cell ALL patients
23. The impact of histological grade on outcomes in follicular lymphoma: An analysis of patients in the SEER database in the context of evolving disease classification and treatment
24. Lamin B1 deletion in myeloid neoplasms causes nuclear anomaly and altered hematopoietic stem cell function
25. CD19 CAR–T cells of defined CD4+: CD8+ composition in adult B cell ALL patients
26. Loss of Lamin B1 in Myeloid Neoplasms with 5q Deletion Causes Myeloid-Biased Hematopoiesis and Pelger-Huet Nuclear Anomaly
27. Reduced-Intensity Therapy with Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) Yields Durable Remissions in Adults with Newly-Diagnosed Acute Lymphoblastic Leukemia/Lymphoma (ALL): Final Results of a Phase II Trial
28. Assessing the added value of bone marrow morphologic evaluation beyond flow cytometry for disease detection in the setting of acute myeloid leukemia after chemotherapy
29. Clinicopathologic Findings in Patients With Initial Diagnosis of Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT) in Colorectal Mucosa
30. Supplemental Material, sj-pdf-3-apc-10.1177_2374289521990823 - Entrustable Professional Activities in Hematopathology Pathology Fellowship Training: Consensus Design and Proposal
31. Supplemental Material, sj-pdf-2-apc-10.1177_2374289521990823 - Entrustable Professional Activities in Hematopathology Pathology Fellowship Training: Consensus Design and Proposal
32. Supplemental Material, sj-pdf-4-apc-10.1177_2374289521990823 - Entrustable Professional Activities in Hematopathology Pathology Fellowship Training: Consensus Design and Proposal
33. Supplemental Material, sj-pdf-1-apc-10.1177_2374289521990823 - Entrustable Professional Activities in Hematopathology Pathology Fellowship Training: Consensus Design and Proposal
34. Does Detection of
35. Resistance to CD38 Antigen Targeted Therapy in Multiple Myeloma May Result from Underrecognized Chromosome 4 Gene Deletions
36. Minimal residual disease testing in acute leukemia
37. How I Diagnose Minimal/Measurable Residual Disease in B Lymphoblastic Leukemia/Lymphoma by Flow Cytometry
38. Myeloperoxidase Expression in B-Lymphoblastic Leukemia by Immunohistochemistry as a Diagnostic Confounder
39. CD33 expression on natural killer cells is a potential confounder for residual disease detection in acute myeloid leukemia by flow cytometry
40. Durable remission of HIV-negative, Kaposi’s sarcoma herpes virus-associated multicentric Castleman disease in patient with rheumatoid arthritis treated with methotrexate
41. Clinicopathologic Findings in Patients With Initial Diagnosis of Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT) in Colorectal Mucosa.
42. Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Final Results from a Prospective Phase II Study
43. Molecular and Cytogenetic Education in Hematopathology Fellowship
44. How I Diagnose Minimal/Measurable Residual Disease in B Lymphoblastic Leukemia/Lymphoma by Flow Cytometry.
45. Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) Is Active and Well-Tolerated in Adults with Newly-Diagnosed Acute Lymphoblastic Leukemia/Lymphoma (ALL): Initial Results of a Phase II Trial
46. Ibrutinib Is Effective in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Results from a Prospective Phase II Study
47. Donor derived T-cell large granular lymphocyte leukemia after cord blood transplant for pediatric T-cell lymphoblastic leukemia
48. Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin
49. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells
50. Poor Outcomes Among Patients Failing Dose-Adjusted EPOCH in Aggressive Lymphoma: A Collaborative, Retrospective Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.